AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28913846
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (220 mL daily for 5 days)
Trial: 28913846
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional medical therapies only)
Trial: 9392401
Drug: Ceftriaxone, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone, 50 mg/kg (single i.m. injection, with a second dose if unsatisfactory response after 48 h)
Trial: 9392401
Drug: Amoxicillin clavulanate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin clavulanate, 12.5 mg tid (10-day course)
Trial: 7930480
Drug: Nicardipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20 mg orally; n = 8)
Trial: 28926120
Drug: Glecaprevir/pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (G/P) for 12 weeks
Trial: 28926120
Drug: Glecaprevir/pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (G/P) for 16 weeks
Trial: 19114761
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and Ketorolac administered 1 hr prior to skin incision
Trial: 19114761
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and Ketorolac administered at peritoneum closure
Trial: 16488321
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg subcutaneous weekly
Trial: 8678775
Drug: Cefotaxime sodium
RxNorm normalized name: Cefotaxime Sodium
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime sodium (1 g)
Trial: 8678775
Drug: Ticarcillin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin plus clavulanic acid (3.1 g)
Trial: 8678775
Drug: Ceftriaxone sodium
RxNorm normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone sodium (1 g)
Trial: 30357332
Drug: G1P[8] rotavirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1P[8] rotavirus vaccine (2-3 doses)
Trial: 30156433
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management for other drug
Trial: 24715424
Drug: Oligofructose (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (30 g day(-1) for 6 weeks)
Trial: 22244522
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 minutes)
Trial: 20807969
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (social intervention + antidepressants)
Trial: 14693573
Drug: ADP receptor
RxNorm normalized name: ADP-597
DrugBank: ADP-597 (DB12084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADP receptor antagonist alone
Trial: 14693573
Drug: ADP receptor
RxNorm normalized name: ADP-597
DrugBank: ADP-597 (DB12084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADP receptor antagonist plus IV heparin
Trial: 11964722
Drug: Dietary antioxidants;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary antioxidants; specific dosage and duration not available
Trial: 9721148
Drug: Budesonide enema
RxNorm normalized name: budesonide Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide enema 2.0 mg/100 mL
Trial: 9721148
Drug: Budesonide enema
RxNorm normalized name: budesonide Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide enema 8.0 mg/100 mL
Trial: 9721148
Drug: Budesonide enema
RxNorm normalized name: budesonide Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide enema (both doses)
Trial: 3056816
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human proinsulin (assumed potency 4 U/mg)
Trial: 219500
Drug: Antacid mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid mixture plus sulpiride
Trial: 219500
Drug: Antacid mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid mixture alone
Trial: 27838576
Drug: Snapshot‐Freeze (SSF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snapshot‐Freeze (SSF) with beta-blockers (BB)
Trial: 27838576
Drug: Snapshot‐Freeze (SSF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snapshot‐Freeze (SSF) without beta-blockers (non-BB)
Trial: 27838576
Drug: Standard reconstruction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard reconstruction (STD) with beta-blockers (BB)
Trial: 27838576
Drug: Standard reconstruction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard reconstruction (STD) without beta-blockers (non-BB)
Trial: 15180019
Drug: Midazolam (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (starting dose of 0.1 mg/kg/h)
Trial: 15180019
Drug: Dexmedetomidine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (starting dose of 0.25 microg/kg/h)
Trial: 15180019
Drug: Dexmedetomidine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (starting dose of 0.5 microg/kg/h)
Trial: 7817169
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no heparin prophylaxis)
Trial: 3043128
Drug: Cytoprotective antacidum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoprotective antacidum (226 mval acid‐neutralisation‐capacity per day's dose)
Trial: 3043128
Drug: Cimetidine (2x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (2x 400 mg)
Trial: 3043128
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination treatment of antacidum with Cimetidine for 1 week, followed by antacidum
Trial: 28336937
Drug: FCM-miniR (mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCM-miniR (mitoxantrone with low-dose rituximab)
Trial: 19329405
Drug: High-dose multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose multivitamin and mineral supplement (MMS)
Trial: 19329405
Drug: Low-dose MMS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MMS
Trial: 16394956
Drug: Antioxidants (AO)
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (AO) - 1000 mg vitamin C and 300 mg RRR‐alpha‐tocopheryl acetate
Trial: 11345029
Drug: Ukrain 50
RxNorm normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain 50 mg (5 mg every second day for a total of 10 injections)
Trial: 11345029
Drug: Ukrain 100
RxNorm normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain 100 mg (10 mg injections)
Trial: 11345029
Drug: Symptomatic corrective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic corrective therapy (control group)
Trial: 1622919
Drug: Erythromycin, 500
RxNorm normalized name: Erythromycin, 500 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 500 mg twice a day for 7 1/2 days starting the evening before the abortion
Trial: 6691563
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg orally with a sip of water 1‐4 hr before induction)
Trial: 6691563
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg orally with a sip of water 1‐4 hr before induction) + Glycopyrrolate (4‐5 micrograms/kg intramuscularly 45‐90 min before induction)
Trial: 30021588
Drug: Best current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best current treatment plus ultrasound-guided intra-articular hip injection of corticosteroid (triamcinolone acetonide 40 mg) with 1% lidocaine hydrochloride
Trial: 30021588
Drug: Best current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best current treatment plus ultrasound-guided intra-articular hip injection of 1% lidocaine hydrochloride alone
Trial: 30021588
Drug: Best current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best current treatment alone
Trial: 18338275
Drug: 3‐in‐1 block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐in‐1 block with 40 ml of 0.25% bupivacaine 30‐minutes before surgery
Trial: 7574952
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin according to the 'Hammersmith' regimen
Trial: 2117207
Drug: Inositol (INO)
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol (INO) supplementation (70‐100 mg/kg/day)
Trial: 21495829
Drug: bisoprolol/hydrochlorothiazide 5/6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol/hydrochlorothiazide 5/6.25 mg
Trial: 21495829
Drug: amlodipine/valsartan 5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine/valsartan 5/160 mg
Trial: 15323587
Drug: Quetiapine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (300 mg/day, titrated upward)
Trial: 9875113
Drug: Intracoronary GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary GTN (0.2 mg)
Trial: 9875113
Drug: ISDN spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN spray (0.8 mg)
Trial: 9875113
Drug: Sublingual GTN
RxNorm normalized name: GTN Sublingual Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual GTN capsule (0.8 mg)
Trial: 9054791
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (graded activity and cognitive restructuring)
Trial: 31533823
Drug: Weekly reminder
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly reminder e-mails
Trial: 21055739
Drug: CDB-2914 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 (20 mg)
Trial: 21055739
Drug: CDB-2914 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 (10 mg) and CDB-2914 (20 mg)
Trial: 18204878
Drug: Durasphere anal
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durasphere anal injection (mean of 8.8 ml injected)
Trial: 17154744
Drug: Active high-dose
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active high-dose (35 mg) 24-hr patches
Trial: 8515294
Drug: Ciprofloxacin plus
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin plus amoxicillin
Trial: 9055918
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy, 1 IU/kg/week, administered subcutaneously once daily
Trial: 1841830
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (ivIgG) for prophylaxis of infection
Trial: 1841830
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (ivIgG)
Trial: 6357269
Drug: Stilboestrol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stilboestrol therapy (mean dose of about 11.5 g starting at the 12th week of pregnancy)
Trial: 6357269
Drug: Stilboestrol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stilboestrol therapy
Trial: 17311979
Drug: Probiotics (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (various strains including Lactobacillus rhamnosus GG, L. reuteri, L. casei, L. acidophilus, Escherichia coli strain Nissle 1917, certain bifidobacteria, Enterococcus faecium SF68, Saccharomyces boulardii)
Trial: 15081569
Drug: ximelagatran 30
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ximelagatran 30 mg
Trial: 15081569
Drug: ximelagatran 60
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ximelagatran 60 mg
Trial: 9291
Drug: Chlorthalidone 50
RxNorm normalized name: chlorthalidone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50 mg/day
Trial: 4364175
Drug: Isoprinosine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprinosine (6 g daily for 7 days)
Trial: 25023847
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate formulation A (2g)
Trial: 25023847
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate formulation B (2g)
Trial: 16508278
Drug: 150 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mmol/l calcium lactate prerinse
Trial: 16508278
Drug: 30 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mmol/l calcium lactate prerinse
Trial: 16508278
Drug: 300 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mmol/l calcium lactate prerinse
Trial: 12861344
Drug: 10% Pentastarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Pentastarch infusion (500 ml)
Trial: 12861344
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (60 ml) placebo infusion
Trial: 11060526
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin G (IVIgG), 1 g/kg body weight, given on days 0, 3, 7, 14, and 21
Trial: 11060526
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (comparison group with IgG levels >4 g/L)
Trial: 29725191
Drug: SISTAS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SISTAS intervention (12 weekly classes followed by nine monthly booster sessions)
Trial: 22673035
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (n=17), 12 sessions of 40 minutes each, three days/week for four weeks.
Trial: 16241919
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment and regular monitoring (Group B)
Trial: 12362930
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg/kg body weight, intravenous infusion)
Trial: 7587918
Drug: Multiple insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple insulin injection treatment (MIT) group
Trial: 7587918
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin injection treatment (CIT) group
Trial: 1971955
Drug: 15 or
RxNorm normalized name: Oseni 25/15 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 or 30 mg flurazepam
Trial: 1971955
Drug: 0.25 or
RxNorm normalized name: Renese-R 2/0.25 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 or 0.50 mg triazolam
Trial: 922640
Drug: No-feedback or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-feedback or no-treatment
Trial: 30879734
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of supplemental parenteral nutrition (PN) after one week
Trial: 30879734
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of supplemental parenteral nutrition (PN) within 24 hours
Trial: 27964826
Drug: UC-MSC treatment
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC treatment (1.0 × 10^6 MSCs per kg body weight, six doses through peripheral intravenous infusion)
Trial: 21771279
Drug: Internet-based psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based psychological treatment program (Revive) consisting of communication skills training, sensate focus exercises, and regular contact with a therapist
Trial: 16534755
Drug: Gd-DTPA-DeA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gd-DTPA-DeA (all doses)
Trial: 14635462
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a grass extract (ALK‐Abellò)
Trial: 8957141
Drug: Enhanced day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced day treatment program plus abstinent contingent work therapy and housing (EC)
Trial: 1568426
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg quinapril (single dose)
Trial: 1568426
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg quinapril twice daily for 14 days
Trial: 3894337
Drug: Molindone (injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molindone (injection for 2-3 days, then oral for up to 4 weeks)
Trial: 3894337
Drug: Haloperidol (injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (injection for 2-3 days, then oral for up to 4 weeks)
Trial: 3894337
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Molindone and Haloperidol)
Trial: 30268156
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell intradermal vaccinations (two courses of four daily doses)
Trial: 27352491
Drug: Oblique insertion
RxNorm normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oblique insertion therapy at anatomical points
Trial: 24212124
Drug: 3‐month exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐month exercise intervention (160 min·wk of moderate‐intensity aerobic walking, twice weekly resistance training with resistance bands)
Trial: 22950925
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (exposed to video, audio, and print advertisements promoting parent-child communication about delaying sexual activity)
Trial: 22950925
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not exposed to the treatment messages)
Trial: 20230859
Drug: Glucose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose administration (dose not specified)
Trial: 20230859
Drug: Glucose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose administration (regardless of dose or dual-task conditions)
Trial: 8466238
Drug: Nebulised budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised budesonide suspension
Trial: 30695078
Drug: Mobile phone
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone app providing ACH antibiotic guidelines
Trial: 24216616
Drug: fampridine-SR 25
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fampridine-SR 25 mg twice daily
Trial: 21882176
Drug: Acitretin 25
RxNorm normalized name: acitretin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin 25 mg orally 5 days per week
Trial: 9184881
Drug: Emergency medical
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency medical therapy (intravenous vasopressin and esophageal balloon tamponade) followed by elective portacaval shunt in survivors (22 patients)
Trial: 9184881
Drug: Emergency medical
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency medical therapy and elective shunt
Trial: 7682261
Drug: Aspirin 60-80
RxNorm normalized name: aspirin 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 60-80 mg/kg alone (Group A)
Trial: 7682261
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus intravenous gamma globulin (IVGG) 400 mg/kg for 5 days (Group B)
Trial: 7682261
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus a single dose of IVGG 2.0 gm/kg (Group C)
Trial: 22551107
Drug: EDP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP plus mitotane (second-line therapy)
Trial: 22551107
Drug: Streptozocin plus
RxNorm normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Streptozocin plus mitotane (second-line therapy)